Mersana Therapeutics, Inc.
MRSN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $175,232 | $269,382 | $548,814 | $439,013 |
| - Cash | $107,750 | $174,561 | $128,885 | $177,947 |
| + Debt | $28,598 | $33,830 | $36,542 | $38,176 |
| Enterprise Value | $96,080 | $128,651 | $456,471 | $299,242 |
| Revenue | $40,497 | $36,855 | $26,581 | $43 |
| % Growth | 9.9% | 38.7% | 61,716.3% | – |
| Gross Profit | $40,497 | $36,855 | $26,581 | $43 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$63,272 | -$166,080 | -$199,957 | -$167,938 |
| % Margin | -156.2% | -450.6% | -752.3% | -390,553.5% |
| Net Income | -$69,192 | -$171,670 | -$204,212 | -$170,060 |
| % Margin | -170.9% | -465.8% | -768.3% | -395,488.4% |
| EPS Diluted | -14.12 | -36.96 | -54.51 | -60.24 |
| % Growth | 61.8% | 32.2% | 9.5% | – |
| Operating Cash Flow | -$82,340 | -$168,882 | -$49,363 | -$139,988 |
| Capital Expenditures | -$132 | -$2,168 | -$2,197 | -$648 |
| Free Cash Flow | -$82,472 | -$171,050 | -$51,560 | -$140,636 |